A major international Phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab—a medication already prescribed to some patients with MS—significantly slows ...
PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placebo ...
In people with primary progressive multiple sclerosis (PPMS), depressive symptoms measured using the Hospital Anxiety and Depression Scale (HADS) predicted subsequent neurologic disability progression ...
Detailed price information for Zenas Biopharma Inc (ZBIO-Q) from The Globe and Mail including charting and trades.
The proportion of patients with 12-week composite confirmed disability progression was 33 and 40%, respectively, with ocrelizumab and placebo. HealthDay News — For patients with primary progressive ...
A major international phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab – a medication already prescribed to some patients with MS – significantly slows ...
Please provide your email address to receive an email when new articles are posted on . The strongest treatment effect for fenebrutinib was observed from baseline in the 9-Hole Peg Test. Safety ...
Multiple sclerosis is a chronic autoimmune disorder that affects the central nervous system, causing episodes of neurologic dysfunction and often gradual disease progression. The immune system ...
Findings showed treatment with tolebrutinib did not significantly delay disability progression compared with placebo. A phase 3 study evaluating tolebrutinib for the treatment of primary progressive ...
Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and safety in diverse patient populations. The MUSETTE trial confirmed that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results